Shanghai InnoStar Bio-tech Co

Shanghai InnoStar Bio-tech Co Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Shanghai InnoStar Bio-tech Co (688710.SS) as of Oct 20, 2026 is 219.62. In the previous year, Cash Conversion Cycle (CCC) was 248.81 — a change of -11.73% (lower).

Cash Conversion Cycle

219.62

YoY

-11.73%

Last updated:

Cash Conversion Cycle (CCC) of Shanghai InnoStar Bio-tech Co is 2025 219.62 . Cash Conversion Cycle (CCC) of Shanghai InnoStar Bio-tech Co was 2024 248.81 . It decreases by -11.73% lower compared to the previous year.

The Shanghai InnoStar Bio-tech Co Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2021
319.01 CNY
Jan 1, 2022
400.84 CNY
Jan 1, 2023
358.25 CNY
Jan 1, 2024
248.81 CNY
Jan 1, 2025
219.62 CNY
The Shanghai InnoStar Bio-tech Co Cash Conversion Cycle history
YEARCash Conversion CycleYoY
219.62-11.73%
248.81-30.55%
358.25-10.62%
400.84+25.65%
319.01—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shanghai InnoStar Bio-tech Co Stock analysis

What does Shanghai InnoStar Bio-tech Co do? Shanghai InnoStar Bio-tech Co Ltd generates revenue through biopharmaceutical non-clinical research services, primarily targeting pharmaceutical companies and biotech firms. The company offers early drug development evaluation services that develop multiple early toxicity rapid prediction and screening models. Non-clinical research services include non-clinical safety evaluation, non-clinical pharmacokinetic research, and non-clinical pharmacodynamic research. Clinical testing and translational research provides analytical methods and data support for clinical pharmacokinetics, efficacy, and safety research of innovative drug projects. The firm's clients are pharmaceutical companies and biotech firms seeking to advance innovative drug projects through non-clinical and clinical research. These clients purchase the company's services to support early drug development, safety evaluation, and translational research needs. The company's focus on biopharmaceutical non-clinical research positions it to serve the growing demand for specialized research services in the life sciences sector. Shanghai InnoStar Bio-tech Co Ltd's service portfolio is structured around three core areas: early drug development evaluation, non-clinical research, and clinical testing and translational research. Each segment provides specialized services that support different stages of drug development, from initial toxicity screening to clinical research support. The company's revenue is derived from these specialized service offerings delivered to pharmaceutical and biotech clients. Shanghai InnoStar Bio-tech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shanghai InnoStar Bio-tech Co stock

Cash Conversion Cycle (CCC) of Shanghai InnoStar Bio-tech Co is 219.62 in 2025.

Cash Conversion Cycle (CCC) of Shanghai InnoStar Bio-tech Co changed from 248.81 to 219.62, representing a -11.73% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Shanghai InnoStar Bio-tech Co since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Shanghai InnoStar Bio-tech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Shanghai InnoStar Bio-tech Co

All Key Metrics — Shanghai InnoStar Bio-tech Co